Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

This study has been completed.
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Dara S. Manoach, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
First received: January 29, 2009
Last updated: October 25, 2013
Last verified: October 2013

This study will determine whether eszopiclone will normalize sleep patterns and restore sleep-dependent enhancement of motor skill learning in patients with schizophrenia. The investigators will compare subjects taking a placebo to those taking 3 mg of eszopiclone with regard to: sleep architecture and sleep latency as measured by actigraphy and polysomnography and sleep-dependent motor skill learning.

Condition Intervention
Drug: eszopiclone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Sleep-dependent motor skill learning [ Time Frame: Day 4 of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sleep architecture and sleep latency as measured by polysomnography [ Time Frame: during four nights in GCRC ] [ Designated as safety issue: No ]

Enrollment: 45
Study Start Date: September 2006
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eszopiclone
3mg of eszopiclone on two consecutive nights
Drug: eszopiclone
3 mg of eszopiclone at bedtime on two consecutive nights
Other Name: Lunesta


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically stable outpatients with DSM-IV diagnoses of Schizophrenia

Exclusion Criteria:

  • History of neurologic or psychiatric disease other than schizophrenia
  • Substance abuse or dependence within the past six months
  • Other chronic medical conditions that affect sleep
  • Pregnancy/breast feeding
  • Hepatic impairment
  • Treatment with metabolic inhibitors or inducers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00833547

United States, Massachusetts
Mass General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Principal Investigator: Dara S. Manoach, PhD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Dara S. Manoach, PhD, Associate Professor of Psychology, Dept. of Psychiatry, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00833547     History of Changes
Other Study ID Numbers: Sepracor051
Study First Received: January 29, 2009
Last Updated: October 25, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
procedural learning
motor skill

Additional relevant MeSH terms:
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 28, 2014